Announcement PDF Neuren (NEU) – Change of Director’s Interest Notice 14 June 2023 The attached Appendix 3Y (Change of Director’s Interest Notice) details a sale today of 1,175,000 shares at $13 per share on behalf of Trevor Scott. Trevor has been a non-executive director and major shareholder since Neuren’s inception more than 20 years ago, providing commitment, leadership and financial support during that period. Following the sale he remains a major shareholder, retaining an interest in 2.4 million shares. About Neuren Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. Neuren has granted an exclusive licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide in North America, while retaining all rights outside North America. Neuren is conducting Phase 2 trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. Recognising the urgent unmet need, all programs have been granted “orphan drug” designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases. 1 of 1 Appendix 3Y Change of Director’s Interest Notice Appendix 3Y Rule 3.19A.2 Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity: Neuren Pharmaceuticals Limited ARBN: 111 496 130 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Mr Trevor Donald Scott Date of last notice 11 August 2020 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct and Indirect interest Nature of indirect interest (including registered holder) Beneficiary of Ordinary Shares under registered holders Essex Castle Limited and Centralo Limited. Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 14 June 2023 No. of securities held prior to change 3,589,784 Ordinary shares Class Ordinary shares Number acquired Number disposed 1,175,000 Ordinary shares Value/Consideration $15,275,000 ($13.00 per share) Note: If consideration is non-cash, provide details and estimated valuation No. of securities held after change + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 2,414,784 Ordinary shares Appendix 3Y Change of Director’s Interest Notice Nature of change On-market trade Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract Not applicable Nature of interest Not applicable Name of registered holder (if issued securities) Not applicable Date of change Not applicable No. and class of securities to which Not applicable interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Not applicable Interest disposed Not applicable Value/Consideration Not applicable Note: If consideration is non-cash, provide details and an estimated valuation Interest after change Not applicable Part 3 – +Closed period Were the interests in the securities or contracts detailed No above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade Not applicable to proceed during this period? If prior written clearance was provided, on what date was this Not applicable provided? + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011